Send to

Choose Destination
Oncoimmunology. 2014 Dec 13;3(9):e954919. eCollection 2014 Oct.

Tumor-associated antigen specific CD8+ T cells in hepatocellular carcinoma - a promising target for immunotherapy.

Author information

Department of Medicine II; University Hospital Freiburg ; Freiburg, Germany.
Department of Medicine II; University Hospital Freiburg ; Freiburg, Germany ; Spemann Graduate school of Biology and Medicine (SGBM); Albert-Ludwigs University ; Freiburg, Germany ; Faculty of Biology; Albert-Ludwigs University ; Freiburg, Germany.


Immunotherapy is a promising treatment option for patients with hepatocellular carcinoma (HCC). Indeed, CD8+ T-cell responses against various tumor antigens occur in these patients. However, these antitumoral T cells show a severely impaired effector function. Several immunosuppressive mechanisms contribute to this T-cell failure, including regulatory T cells and inhibitory receptors.


AFP, α-fetoprotein; CD8+ T cells; HCC, hepatocellular carcinoma; HLA, human leukocyte antigen; IFNγ, interferon-γ; IL, interleukin; MAGE-A1, melanoma-associated gene-A1; NY-ESO-1, New York-esophageal squamous cell carcinoma-1; PD-1; PD-1, programmed death-1; PD-L1, PD-ligand-1; T-cell failure; TAA, tumor-associated antigen; Treg, regulatory T cells; hepatocellular carcinoma; immunotherapy; melanoma; regulatory T cells; tumor-associated antigens

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center